Definitive Contract 75N92021C00007

Award Date 2/1/21
Potential Completion Date 2/1/23
Potential Value $10M
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
South Korea
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Genedx, LLC, a wholly owned subsidiary of Opko Health, Inc. The contract provides laboratory testing services, including genetic testing and diagnostic services, to support research and clinical programs at the NIH. The contract has a ceiling value of $5,775 and a period of performance through May 22, 2023. The contract was awarded on...
Genedx, LLC, a division of Opko Health, Inc., has been awarded a $25,000 firm fixed price purchase order by the National Institutes of Health's National Human Genome Research Institute to provide exome and genome sequencing with optional mitochondrial testing for various patients. The contract has a period of performance of just over one year, running from September 2023 through August 2024. Genedx will perform the sequencing and testing services at its laboratory location in Montgomery Village,...
This firm fixed-price purchase order was awarded by the Office of the Chief Operating Officer (a civilian agency), a component of the National Institutes of Health (NIH), to Genedx, LLC, a for-profit limited liability company. The $81,666 contract is for medical laboratory testing services, specifically genetic testing and diagnostic services. Genedx, a wholly owned subsidiary of Opko Health, Inc., provides comprehensive genetic testing, including mutation analysis, exome and genome...
This federal contract award is for medical laboratory testing services and was issued by the National Institutes of Health (NIH) Clinical Center to Genedx, LLC, a leading provider of genetic testing and diagnostic services. The contract, valued at $81,410.00, is a firm fixed-price purchase order without a set-aside designation, indicating Genedx competed in the open market. Genedx operates from its facilities in Maryland and has held several Indefinite Delivery Vehicle (IDV) contracts with the...
This federal contract award, with ID HHSN269201700325PC, was issued by the National Institutes of Health (NIH) Clinical Center to Genedx, LLC, a for-profit limited liability company. The contract is for $95,385.00 and is for medical laboratory testing services, specifically supporting genetic testing and analysis. The contract is a firm fixed-price purchase order without a set-aside designation, indicating Genedx competed in the open market for this award. Genedx, as a wholly owned subsidiary of...
This firm fixed-price contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Genedx, LLC, a provider of genetic testing and diagnostic services. The $5,250 contract tasks Genedx with providing a range of genetic testing services, including mutation analysis, exome and genome sequencing, gene panel testing, and mitochondrial testing, in support of NIH's clinical research missions. This contract is not set aside for any socioeconomic...
This federal contract award, with an ID of 75N90018K00052, was issued by the National Institutes of Health (NIH) Clinical Center to Genedx, LLC, a for-profit limited liability company. The $82,281.25 firm fixed-price purchase order is for medical laboratory testing services, primarily to support research and clinical programs at the NIH. Genedx, a wholly-owned subsidiary of Opko Health, Inc., is a leading provider of genetic testing and diagnostic services to the federal government. This...
This is a firm fixed-price purchase order contract awarded by the Office of the Chief Operating Officer at the National Institutes of Health (NIH) to Genedx, LLC, a for-profit limited liability company, for medical laboratory testing services. The contract award, valued at $97,833.65, has a performance period from January 14, 2016, to an ultimate completion date of the same day. Genedx, a wholly owned subsidiary of Opko Health, Inc., is a leading provider of genetic testing and diagnostic...
This federal contract award is for medical laboratory testing services provided by Genedx, LLC to the National Institutes of Health (NIH) Clinical Center. The contract, valued at $100,000.00, is a firm fixed-price purchase order with an ultimate completion date of August 12, 2015. Genedx, a for-profit limited liability company, has been a provider of genetic testing services to the NIH, supporting various research and clinical programs, particularly at the NIH Clinical Center and the National...
This federal contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Human Genome Research Institute to Genedx, LLC, a subsidiary of Opko Health, Inc. The $25,000.00 firm fixed-price purchase order is for the provision of genetic testing services, including mutation analysis, exome and genome sequencing, gene panel testing, and mitochondrial testing. The contract has a completion date of June 30, 2025. Genedx is the prime...

Genbody Inc. was awarded a definitive contract valued at $10.3 million by the National Institutes of Health's National Heart, Lung and Blood Institute to support the Rapid Acceleration of Diagnostics Technology Program, Project 6658. Under this firm fixed-price contract, Genbody will deliver diagnostic technologies to HHS/NIH over a two-year period of performance based in South Korea. The Rapid Acceleration program aims to expedite the development and review of critical medical diagnostics, supported here through Genbody's work on new testing capabilities without any identified subcontractors. This NIH contract utilizes the company's international locations to help achieve important public health goals stateside.

Generated 12/25/23, 4:58 AM